Breast Cancer News

[imported_Joe]

>Subject: Latest Breast Cancer Treatment Data - Independent Conference
>Coverage
>Date: Fri, 3 Jun 2005 18:15:55 -0400 (EDT)
>
>================================================== ==========
> Clinical Care Options for Oncology and Hematology
>------------------------------------------------------------
>
>Clinical Oncology
>
>CCO Independent Conference Coverage of the 2005 American Society of
>Clinical Oncology Annual Meeting*
>May 13-17, 2005 - Orlando, Florida
>
>*CCO is an independent medical education company that provides
>state-of-the-art medical information
>to healthcare professionals through conference coverage and other
>educational programs.
>
>Capsule Summaries
>
> * Dietary Fat Reduction Improves Relapse-Free Survival in Postmenopausal
>Women Previously Treated For Early Stage Breast Cancer
> http://clinicalcareoptions.com/onco/conf/o...o2005/cs/10.asp (http://clinicalcareoptions.com/onco/conf/orlando2005/cs/10.asp)
>
> * Long-Term Statin Therapy Reduces Incidence of Breast Cancer
> http://clinicalcareoptions.com/onco/conf/o...2005/cs/514.asp (http://clinicalcareoptions.com/onco/conf/orlando2005/cs/514.asp)
>
> * Circulating Cell Changes Predict Response in Advanced Breast Cancer
>Patients Receiving Bevacizumab and Erlotinib
> http://clinicalcareoptions.com/onco/conf/o...2005/cs/525.asp (http://clinicalcareoptions.com/onco/conf/orlando2005/cs/525.asp)
>
> * Trastuzumab Toxicity Acceptable When Added to Adjuvant Pacitaxel and
>Doxorubicin/Cyclophosphamide for Early Breast Cancer
> http://clinicalcareoptions.com/onco/conf/o...2005/cs/556.asp (http://clinicalcareoptions.com/onco/conf/orlando2005/cs/556.asp)
>
> * Receptor Tyrosine Kinase Inhibitor SU11248 Safe and Active in Heavily
>Pretreated Patients With Metastatic Breast Cancer
> http://clinicalcareoptions.com/onco/conf/o...2005/cs/563.asp (http://clinicalcareoptions.com/onco/conf/orlando2005/cs/563.asp)
>
> * New Taxane Derivative Shows Activity in Metastatic Breast Cancer
>Patients Previously Treated With Taxanes
> http://clinicalcareoptions.com/onco/conf/o...2005/cs/565.asp (http://clinicalcareoptions.com/onco/conf/orlando2005/cs/565.asp)
>
> * Autologous Transplant With High-Dose Chemotherapy Not Warranted for
>Patients With Primary Breast Cancer and ¡Ý 4 Positive Nodes
> http://clinicalcareoptions.com/onco/conf/o...2005/cs/572.asp (http://clinicalcareoptions.com/onco/conf/orlando2005/cs/572.asp)
>
> * Gemcitabine and Capecitabine Combinations Have Similar Efficacy But
>Different Safety Profiles in Metastatic Breast Cancer
> http://clinicalcareoptions.com/onco/conf/o...2005/cs/581.asp (http://clinicalcareoptions.com/onco/conf/orlando2005/cs/581.asp)
>
> * Addition of Prophylactic Growth Factors to Docetaxel-based Chemotherapy
>Improves Toxicity and Quality of Life in Patients With Node-Negative Breast
>Cancer
> http://clinicalcareoptions.com/onco/conf/o...2005/cs/604.asp (http://clinicalcareoptions.com/onco/conf/orlando2005/cs/604.asp)
>
> * HER-2 Overexpression, PR Negativity, and High Ki-67 Expression Predict
>Poor Response in Node-Positive Breast Cancer Patients
> http://clinicalcareoptions.com/onco/conf/o...2005/cs/605.asp (http://clinicalcareoptions.com/onco/conf/orlando2005/cs/605.asp)
>
> * Dose-Dense Chemotherapy Feasible in Early Breast Cancer
> http://clinicalcareoptions.com/onco/conf/o...2005/cs/616.asp (http://clinicalcareoptions.com/onco/conf/orlando2005/cs/616.asp)
>
> * Bevacizumab Added to Paclitaxel Significantly Prolongs Progression-free
>Survival and Improves Response Rate in Patients With Locally Recurrent or
>Metastatic Breast Cancer
> http://clinicalcareoptions.com/onco/conf/o...005/cs/9002.asp (http://clinicalcareoptions.com/onco/conf/orlando2005/cs/9002.asp)
>
>Headlines
> * Raloxifene may decrease risk of endometrial cancer
> http://clinicalcareoptions.com/onco/news/n...do2005_5001.asp (http://clinicalcareoptions.com/onco/news/news_orlando2005_5001.asp)
>
> * New Drug Active in Imatinib-Resistant Leukemias
> http://clinicalcareoptions.com/onco/news/n...do2005_3015.asp (http://clinicalcareoptions.com/onco/news/news_orlando2005_3015.asp)
>
>These Capsule Summaries and Headlines are located online at:
>http://clinicaloptions.com/onco/conf/orlando2005/
>
>------------------------------------------------------------
>Coming Soon: CME-Certified Expert Analyses
>
>Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care
>Options, LLC.
>
>Supported by educational grants from Aventis Pharmaceuticals, a member of
>the sanofi-aventis Group,
>Genomic Health, Millennium, Novacea, Pfizer, and Roche Pharmaceuticals.
>
>------------------------------------------------------------
>
>To unsubscribe from this newsletter, please send an email to
>info@clinicaloptions.com with "unsubscribe" in the subject line.
>
>Copyright 2005 Clinical Care Options, LLC. All rights reserved.
>1894 Preston White Drive, Suite 110
>Reston, VA 20191-5433
>